Vertis raises $37 million in venture financing:
This article was originally published in Clinica
Vertis Neuroscience, which develops devices for treating diseases and disorders of the nervous system, has closed a $37 million round of venture financing. The Seattle-based company has developed the Vertis PNT, a minimally invasive, nonsurgical treatment for low back pain through the delivery of electrical stimulation to the deep tissues near the spine. The product received FDA clearance in December 2001. Proceeds from the financing will be used to support sales and marketing of the product. The new investors include Johnson & Johnson Development, J&J's venture capital company.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.